中国肺癌杂志2024，Vol.27Issue(12)：956-960,5.DOI:10.3779/j.issn.1009-3419.2024.102.37
克唑替尼治疗洛拉替尼耐药伴MET扩增的EML4-ALK基因融合阳性晚期肺腺癌1例
Crizotinib Treatment for Lorlatinib-resistant MET-amplified EML4-ALK-fusion Positive Advanced Lung Adenocarcinoma:A Case Report
摘要
Abstract
Lung cancer is a major cause of cancer-related mortality worldwide.Among patients with non-small cell lung cancer(NSCLC),approximately 3%-7%harbor anaplastic lymphoma kinase(ALK)gene fusions.In recent years,multiple tyrosine kinase inhibitors(TKIs)have significantly improved the survival of patients with metastatic ALK-positive NSCLC.However,disease progression due to resistance remains a challenge.This article retrospectively analyzes a case of advanced lung adenocarcinoma with the echinoderm microtubule associated protein like 4(EML4)-ALK fusion variant 3(V3).The patient developed resistance to Lorlatinib treatment accompanied by mesenchymal-epithelial transition factor(MET)amplification.Effective tumor control was achieved with the combined use of Crizotinib and Lorlatinib,providing a valuable reference for further exploration of treatment strategies following resistance to ALK-TKIs in clinical practice.关键词
肺肿瘤/ALK基因融合/MET扩增/洛拉替尼/克唑替尼/分子靶向治疗Key words
Lung neoplasms/ALK gene fusion/MET amplification/Lorlatinib/Crizotinib/Molecularly targeted therapy引用本文复制引用
王欣怡,穆宁,刘梅,徐悦,吴盛楠,吕欢,马春华..克唑替尼治疗洛拉替尼耐药伴MET扩增的EML4-ALK基因融合阳性晚期肺腺癌1例[J].中国肺癌杂志,2024,27(12):956-960,5.基金项目
This paper was supported by the grant from Tianjin Key Medical Discipline(Specialty)Construction Project(No.TJYXZDXK-053B)(to Chunhua MA). 本文受天津市医学重点学科(专科)建设项目(No.TJYXZDXK-053B)资助 （Specialty）
